Influenza vaccination and asthma: current studies and recommendations

Area of Science:

• Immunology
• Pulmonology
• Vaccinology

Background:

• Influenza is a significant cause of morbidity and mortality, particularly in individuals with pre-existing conditions like asthma.
• Influenza vaccines have been available for decades, yet uptake remains low, even in high-risk asthmatic populations.
• Concerns exist regarding potential adverse effects of influenza vaccination, such as exacerbations of asthma.

Purpose of the Study:

• To review the evidence regarding the safety and efficacy of influenza vaccination in patients with asthma.
• To assess whether influenza vaccination exacerbates chronic airflow obstruction, including asthma.
• To consider novel vaccine technologies and their potential use in asthmatic individuals.

Main Methods:

• Review of observational studies and placebo-controlled trials on influenza vaccination in asthmatic patients.
• Analysis of data on post-immunization changes in bronchial hyperreactivity and bronchodilator use.
• Consideration of intranasal live-attenuated and nucleic acid-based influenza vaccines.

Main Results:

• Observational studies show conflicting results regarding post-vaccination asthma exacerbations.
• Placebo-controlled trials have not demonstrated significant clinical deterioration, though minor effects on lung function were noted in one study.
• Limited data suggest live-attenuated influenza vaccines may be safely administered to asthmatic patients.

Conclusions:

• Influenza infection causes significant morbidity in asthma patients.
• The benefits of influenza vaccination in asthmatics appear to outweigh potential risks, despite limited robust evidence.
• Further placebo-controlled trials with larger numbers of asthmatic patients are warranted to definitively establish vaccine safety.